BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Specialised Therapeutics and DKSH partner to expand access to cancer medicines in Vietnam

November 23, 2026 | News

Collaboration will directly target two major areas of concern: breast cancer and lung cancer



Singapore-based biopharmaceutical company Specialised Therapeutics (ST) and DKSH have signed an exclusive strategic partnership to bring innovative oncology therapies to patients across Vietnam.

According to 2022 GLOBOCAN estimates from the World Health Organization, Vietnam faces a significant and growing cancer burden, with approximately 180,000 new cases and over 120,000 deaths reported annually.

The collaboration will directly target two major areas of concern: breast cancer, which is the most frequently diagnosed cancer among Vietnamese women, and lung cancer, a leading cause of cancer-related mortality (GLOBOCAN 2022).

ST currently commercialises oncology products under exclusive licenses covering Southeast Asia, Australia, and New Zealand. The company has successfully secured regulatory approvals in major markets including Australia, New Zealand, Singapore, Thailand, and Malaysia.

According to ST, this new partnership in Vietnam strategically extends its regional model into one of Southeast Asia's largest and fastest-growing healthcare markets.

"Vietnam is a priority market for ST, and the right partner makes all the difference," said Carlo Montagner, Chief Executive Officer of Specialised Therapeutics. "DKSH brings deep local market knowledge and expertise, and we look forward to introducing several vital cancer medicines to patients in Vietnam over the next few years."